EGFR Resisters and LUNGevity Support Research into TKI-Induced NSCLC Transformation
Approximately 23% of non-small cell lung cancer (NSCLC) have an EGFR-positive mutation. Advanced-stage NSCLC patients whose tumors have an EGFR mutation are often treated with one